MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Ouyang, Mao ^a,b   Li, Yongxin ^a   Ye, Sheng ^a   Ma, Jieyi ^a   Lu, Liming ^a   Lv, Weiming ^a   Chang, Guangqi ^a   Li, Xiaoxi ^a   Li, Qing ^b   Wang, Shenming ^a   Wang, Wenjian ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Center for Stem Cell Biology and Tissue Engineering   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MICRORNA; MICRORNA 10B 5P; MICRORNA 125B 5P; MICRORNA 130A 3P; MICRORNA 155 5P; MICRORNA 181A 5P; MICRORNA 181B 5P; MICRORNA 183 5P; MICRORNA 195 5P; MICRORNA 21 3P; MICRORNA 31 5P; MICRORNA 451A; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; MIRN132 MICRORNA, HUMAN; MIRN451 MICRORNA, HUMAN;

ADULT; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL ASSAY; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; CELL LINE; CELL SURVIVAL; CLUSTER ANALYSIS; DNA MICROARRAY; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CLUSTER ANALYSIS; COMBINED MODALITY THERAPY; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84900397618     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096228     Document Type: Article

References (40)

1. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-Negative Breast Cancer. N Engl J Med 363: 1938-1948.
2. Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, et al. (2010) Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 4: 209-229.
3. Oakman C, Moretti E, Galardi F, Biagioni C, Santarpia L, et al. (2011) Adjuvant systemic treatment for individual patients with triple negative breast cancer. Breast 20: 135-141.
4. André F, Zielinski CC (2012) Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol 23: 46-51.
5. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
6. Wang B, Wang H, Yang Z (2012) MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R. PLoS One 7:e47053.
7. Wu ZS, Wu Q, Wang CQ, Wang XN, Huang J, et al. (2011) miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met. Cancer 117: 2842-2852.
8. Rehman SK, Li SH, Wyszomierski SL, Wang Q, Li P, et al. (2013) 14-3-3ζ Orchestrates Mammary Tumor Onset and Progression via miR221-Mediated Cell Proliferation. Cancer Res doi: 10.1158/0008-5472.CAN-13- 2016.
9. Falkenberg N, Anastasov N, Rappl K, Braselmann H, Auer G, et al. (2013) MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion. Br J Cancer 109: 2714-2723.
10. Lei L, Huang Y, Gong W (2013) miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. Oncol Rep 30: 2897-2902.
11. Fassan M, Baffa R, Palazzo JP, Lloyd J, Crosariol M, et al. (2009) MicroRNA expression profiling of male breast cancer. Breast Cancer Res 11: R58.
12. Li JH, Liu S, Zhou H, Qu LH, Yang JH (2013) StarBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res doi:10.1093/nar/gkt1248.
13. Saito R, Smoot ME, Ono K, Ruscheinski J, Wang LP, et al. (2012) A travel guide to Cytoscape plugins. Nat Methods 9(11): 1069-1076.
14. Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, et al. (2011) MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res 71: 4443-4453.
15. Boll K, Reiche K, Kasack K, Mörbt N, Kretzschmar AK, et al. (2013) MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 32: 277-285.
16. Yang L, Li N, Wang H, Jia X, Wang X, et al. (2012) Altered microRNA expression in cisplatin-resistant ovarian cancer cells and up-regulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol. Rep 28: 592-600.
17. Xu N, Shen C, Luo Y, Xia L, Xue F, et al. (2012) Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem Biophys Res Commun 425: 468-472.
18. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, et al. (2008) Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 111: 478-486.
19. Bitarte N, Bandres E, Boni V, Zarate R, Rodriguez J, et al. (2011) MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells 29: 1661-1671.
20. Li HY, Zhang Y, Cai JH, Bian HL (2013) MicroRNA-451 inhibits growth of human colorectal carcinoma cells via down-regulation ofPi3k/Akt pathway. Asian Pac J Cancer Prev 14: 3631-3634.
21. Wang R, Wang ZX, Yang JS, Pan X, De W, et al. (2011) MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene 30: 2644-2658.
22. Li HY, Zhang Y, Cai JH, Bian HL (2013) MicroRNA-451 inhibits growth of human colorectal carcinoma cells via downregulation ofPi3k/Akt pathway. Asian Pac J Cancer Prev 14: 3631-3634.
23. Chen H, Untiveros GM, McKee LA, Perez J, Li J, et al. (2012) Micro-RNA-195 and -451 regulate the LKB1/AMPK signaling axis by targeting MO25. PLoS One 7: e41574.
24. Bergamaschi A, Katzenellenbogen BS (2012) Tamoxifen downregulation of miR-451 increases 14-3-3f and promotes breast cancer cell survival and endocrine resistance. Oncogene 31: 39-47.
25. Jiao Y, Bishop CE, Lu B (2012) Mex3c regulates insulin-like growth factor 1 (IGF1) expression and promotes postnatal growth. Mol Biol Cell 3: 1404-1413.
26. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, et al. (2008) Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7(7): 2152-2159.
27. Bian HB, Pan X, Yang JS, Wang ZX, De W (2011) Up-regulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res 30: 20.
28. Yu Y, Wang Y, Ren X, Tsuyada A, Li A, et al. (2010) Context-dependent bidirectional regulation of the mutS homolog 2 by transforming growth factor b contributes to chemoresistance in breast cancer cells. Mol Cancer Res 8(12): 1633-1642.
29. Yang GD, Huang TJ, Peng LX, Yang CF, Liu RY, et al. (2013) Epstein-Barr Virus Encoded LMP1 Upregulates MicroRNA-21 to Promote the Resistance of Nasopharyngeal Carcinoma Cells to Cisplatin-Induced Apoptosis by Suppressing PDCD4 and Fas-L. PLoS One 8: e78355.
30. Li Y, Li W, Yang Y, Lu Y, He C, et al. (2009) MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res 1286: 13-18.
31. Ling N, Gu J, Lei Z, Li M, Zhao J, et al. (2013) MicroRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma. Oncol Rep 30: 2111-2118.
32. Pu J, Bai D, Yang X, Lu X, Xu L, et al. (2012) Adrenaline promotes cell proliferation and increases chemoresistance in colon cancer HT29 cells through induction of miR-155. Biochem Biophys Res Commun 428: 210-215.
33. Chen Y, Ke G, Han D, Liang S, Yang G, et al. (2014) MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD. Exp Cell Res. 320: 12-20.
34. Liu M, Wang J, Huang H, Hou J, Zhang B, et al. (2013) miR-181a-Twist1 pathway in the chemoresistance of tongue squamous cell carcinoma. Biochem Biophys Res Commun 441: 364-370.
35. Li P, Lu X, Wang Y, Sun L, Qian C, et al. (2010) MiR-181b suppresses proliferation of and reduces chemoresistance to temozolomide in U87 glioma stem cells. J Biomed Res 24: 436-443.
36. Cai B, An Y, Lv N, Chen J, Tu M, et al. (2013) miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2. Oncol Rep 29: 1769-1776.
37. Wang H, Tan G, Dong L, Cheng L, Li K, et al. (2012) Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 7: e34210.
38. Kong F, Sun C, Wang Z, Han L, Weng D, et al. (2011) miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. J Huazhong Univ Sci Technolog Med Sci 31: 543-549.
39. Mitamura T, Watari H, Wang L, Kanno H, Hassan MK, et al. (2013) Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis 2: e40.
40. Nishida N, Yamashita S, Mimori K, Sudo T, Tanaka F, et al. (2012) MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol 19: 3065-3071.